Blog

Filament Health Announces First Dosing in FDA-Approved Psilocin Clinical Trial

Jul 8 • 3 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced the beginning of dosing in the first United States Food and Drug Administration (FDA)-approved clinical trial studying the effects of naturally derived psychedelic drug candidates. The phase one clinical trial, conducted at the University of…

Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023

Jul 7 • 3 min read

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED), a Canadian Biotechnology company committed to discovering and developing psychedelic derived medicines today announced it has developed its initial Phase 1 study plan intended to demonstrate the safety and appropriate dosing range for its proprietary new chemical entity; L-130. It is also announcing the acquisition of a second…

How Can Ancient Medicines Work with the Future of Medicine?: Mindshifting Moments – Stream #3

Jul 6 • 1 min read

We are all aware that psychedelic-assisted therapy might be able to help us, but we also must recognize that wellness is holistic and must be managed across the entire spectrum of well-being. One often overlooked intersection is the use of stem cells. For this Mindshifting Moment, Host Margaret Williamson will speak to the CEO of…

CaaMTech Collaborates with the Alexander Shulgin Research Institute to Study Shulgin Compounds

Jul 6 • 3 min read

CaaMTech, Inc. and the Alexander Shulgin Research Institute, Inc. (ASRI) jointly announced an agreement today to carry out structural and chemical analyses of previously unreported compounds designed and synthesized by the late Dr. Alexander Shulgin. ASRI is a psychedelics discovery, development, and educational organization dedicated to continuing and extending the work of Dr. Alexander “Sasha” Shulgin. …

Psychedelic Sector News – Weekly Extractions: July 5, 2022

Jul 5 • 2 min read

It was somewhat of a shortened week last week considering the leadup to the 4th of July holiday. To add to that, yesterday was Independence Day here in the United States, which meant no “business as usual” and no market activity. Lo and behold, we are now on the other side of the long weekend…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548